Indeed, recent studies have shown that, besides its action as an antagonist of TGF-β1 signaling, Smad7 can interact with a variety of nuclear proteins [31,32], thereby controlling multiple pathways, which could be relevant for IBD. Here, SMAD7 is linked to inflammatory bowel disease.